Thoughts on the FDA Panel on Menopause

Due to a technical glitch, I wasn’t able to get Dr. Larkin to join. (She popped up for about 5 seconds before I lost her).

So, this is a monologue

I reviewed:

The issue with the warning label on Estrogen products and class labeling

Why has it been difficult in the past to change inaccurate warnings on estrogen

The problem with the format and purpose of the meeting yesterday

Why I declined the invitation to participate

Why this FDA approach to changing product levels may backfire with other products

I was a little all over the place, so I may record a separate podcast episode on this topic. So stay tuned!

Thank you

Annie Fenn, MD

,

Tanmeet Sethi, MD

,

Kristen Wisler

,

Diane P

, and many others for tuning into my live video with

Lisa Larkin MD

! Join me for my next live video in the app.